跳至主要内容
临床试验/EUCTR2010-023120-24-NL
EUCTR2010-023120-24-NL进行中(未招募)1 期

itroglycerin's effect on perfusion and hypoxia in human non small cell lung cancer: proof of principle, a phase II trial - Nitroglycerine phase II

MAASTRO clinic0 个研究点开始时间: 2011年10月14日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - Non-small cell lung cancer stage IB-IV
  • - Newly diagnosed stage Ib-III
  • - Stage IV about to start with a new line of chemotherapy.
  • - Diameter of the primary tumour less than 4 cm or patients with larger lesions who are for any of the following reasons not suitable for inclusion in BTV-boost trial:
  • - prior radiotherapy to the thorax
  • - superior vena cava syndrome, malignant pleural effusion or malignant pericardial effusion.
  • - T4 because of multiple nodules in the same or ipsilateral lobe(s).
  • - Post-obstructive atelectasis or infiltration that cannot be distinguished from tumor on a CT-PET scan.
  • - Patients with a diagnosis of other cancer within the last 3-years
  • - WHO performance status 0-2
  • - Willing and able to comply with the study prescriptions
  • - 18 years or older
  • - Ability to give and having given written informed consent before patient registration
  • - No recent (< 3 months) severe cardiac disease (NYHA class >1) (congestive heart failure, infarction)
  • - No radiotherapy in 4 weeks prior to this study
  • - No treatment with investigational drugs in 4 weeks prior to or during this study.
  • - No current treatment with 5-fosfodiesterase inhibitors, calcium antagonists, beta blockers or nitrates.
  • - No known allergy to nitroglycerin or nitroglycerin patch.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • The opposite of the above

研究者

相似试验